Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials
CONCLUSION: Over 24 weeks, relugolix-CT significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma-associated pain.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: LIBERTY 1, NCT03049735; LIBERTY 2, NCT03103087.FUNDING SOURCE: Myovant Sciences GmbH.PMID:35675604 | DOI:10.1097/AOG.0000000000004787 (Source: Obstetrics and Gynecology)
Source: Obstetrics and Gynecology - June 8, 2022 Category: OBGYN Authors: Elizabeth A Stewart Andrea S Lukes Roberta Venturella Juan-Camilo Arjona Ferreira Yulan Li Elke Hunsche Rachel B Wagman Ayman Al-Hendy Source Type: research
